Evidence map›Paper›PMID 29020046›Full record

ArticlePloS one2017

Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis.

Maëna Le Corvec, Caroline Jezequel, Valérie Monbet, Nadia Fatih, Frédéric Charpentier, Hugues Tariel, Catherine Boussard-Plédel, Bruno Bureau, Olivier Loréal, Olivier Sire and 1 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maëna Le CorvecUniversity Bretagne Sud, IRDL, FRE CNRS 3744, Vannes, France.
Caroline JezequelCHU Rennes, Liver disease unit, Rennes, France.
Valérie MonbetIRMAR Mathematics Research Institute of Rennes, UMR-CNRS 6625, Rennes, France.
Nadia FatihDIAFIR, Rennes, France.
Frédéric CharpentierDIAFIR, Rennes, France.
Hugues TarielDIAFIR, Rennes, France.
Catherine Boussard-PlédelEquipe Verres et Céramiques, UMR CNRS 6226 Institut des Sciences Chimiques de Rennes, University of Rennes 1, Rennes, France.
Bruno BureauEquipe Verres et Céramiques, UMR CNRS 6226 Institut des Sciences Chimiques de Rennes, University of Rennes 1, Rennes, France.
Olivier LoréalUniversity of Rennes 1, Rennes, France.
Olivier SireUniversity Bretagne Sud, IRDL, FRE CNRS 3744, Vannes, France.
Edouard Bardou-JacquetIRMAR Mathematics Research Institute of Rennes, UMR-CNRS 6625, Rennes, France.ORCID http://orcid.org/0000-0002-0784-0710

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsPrognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more relevant information by measuring a wider range of metabolic parameters in serum. Here we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6 months survival in patients with ascites and cirrhosis.

methodsPatients with ascites were prospectively included and followed up for 6 months. MIR-FEWS spectra were measured in serum samples. The most informative spectral variables obtained by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model. Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-validation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh and MELD scores.

results119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%). The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88-0.91), the MELD 0.77 (CI95: 0.66-0.89) and Child-Pugh 0.76 (CI95: 0.66-0.88). MELD and Child-Pugh AUROCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively). Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76-0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04-0.90), and the MIR model (p<0.001; OR:0.50; CI95:0.37-0.66), were significantly associated with 6 months mortality.

conclusionsIn this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the management of these patients.

Indexed as

AlgorithmsArea Under CurveAscitesBiomarkersFemaleFibrosisHumansMaleMiddle AgedPrognosisReproducibility of ResultsRisk AssessmentROC CurveSensitivity and SpecificitySerumSpectrophotometry, InfraredBiomarkers

Identifiers

PMID29020046
PMCPMC5636102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.